 |
 |
Now we can say that a 1-year study shows a treatment both protective and restorative! (I copied the link and Conclusions below) Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal Neurosurg Focus 20 (5):E1, 2006 ------------------------------------------------ Conclusions The results from 1-year intraputaminal GDNF infusion in our study are consistent with extensive animal data2,5,7,8,17,20 and the Bristol Phase I trial results,9,13,15 in which it has been stated that trophic factor treatment can be both protective protective and restorative. The recent inconclusive Phase II results12 may be the result of differences in GDNF dosing and delivery protocols. The two safety issues with GDNF-development of antibodies to exogenous GDNF and possible toxic injury to the cerebellum in nonhuman primates-require further study. In this patient group, however, neither clinical manifestations in response to GDNF antibodies nor clinical or imaging evidence of cerebellar lesions were evident. Given the following three considerations: 1) that advanced PD is profoundly debilitating and life-threatening; 2) that the known safety concerns can be closely monitored and medically managed; and 3) that the methodology used in the two Phase I trials shows strong indications of efficacy, we believe that additional Phase II clinical trials are warranted to continue developing the approach featuring intraputaminal delivery of trophic factors for treating PD. http://www.aans.org/education/journa...0-5-1-0976.pdf Peggy ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn